Revenue segments as reported by the company.

Premiums

Services

Investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefits

Operating costs

Depreciation and amortization

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Humana

Humana Inc. engages in the provision of health insurance services. The firm operates through the following segments: Retail, Group and Specialty and Healthcare Services. The Retail segment consists of products sold on a retail basis to individuals including medical and supplemental plans such as Medicare, and State-based contracts. The Group and Specialty segment contains employer group fully-insured commercial medical products and specialty health insurance benefits marketed to individuals and groups, including dental, vision, military services and other supplemental health & voluntary insurance. The Healthcare Services segment offers services such as pharmacy solutions, provider services, clinical care, predictive modeling and informatics to other Humana businesses, as well as external health plan members, and other employers. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Humana exceeds earnings expectations, focuses on value-based care growth

Humana's strong financial performance and growth in value-based care position the company well for future success. Addressing audit error rates, uncertainties around RADV, and managing costs are key challenges. Opportunities in recruiting, revenue growth, and strategic partnerships offer avenues for further growth.

Humana exceeds Q1 expectations, eyes industry growth amidst challenges

Humana's strong Q1 performance and strategic decisions position it well for growth
Challenges like rate disruptions and Medicaid redeterminations require close monitoring
Opportunities in industry growth, member engagement, and benefit enhancements ahead
Commitment to long-term goals and high-quality service evident in company's outlook

Humana meets Q2 expectations, eyes growth in MA platform

Humana's Q2 performance met expectations with a focus on MA platform growth and disciplined investments.
Challenges include higher utilization in Medicare Advantage and broad-based medical cost trends.
Strategic benefits adjustments and competitive positioning present opportunities for growth and margin expansion.
Expectations for 2024 include maintaining market share, offsetting costs, and achieving strong membership growth.

Humana surpasses Q3 earnings expectations, eyes $37 EPS target

Humana's Q3 performance exceeded expectations, with strong membership growth and strategic initiatives driving future profitability.
While facing challenges in benefit ratios and regulatory changes, Humana remains focused on achieving long-term financial targets.
The company's commitment to operational excellence, membership growth, and pricing actions positions it for sustained success.
Strategic partnerships and risk management efforts showcase Humana's resilience and adaptability in a dynamic healthcare landscape.

Humana faces challenges from rising costs but eyes long-term growth

Humana's Q4 2023 earnings call highlighted challenges from increased medical costs and utilization trends impacting financial performance and outlook.
Despite disappointments in short-term results, the company remains confident in the long-term attractiveness of the Medicare Advantage sector.
Strategic efforts to restore margins, address utilization drivers, and engage with providers reflect a proactive approach to managing industry dynamics.
Balancing profitability with membership growth through benefit adjustments and pricing actions is crucial for Humana's sustainable financial performance.

Humana reports solid Q1 performance, eyes margin recovery in 2025

Humana's Q1 2024 earnings call highlighted a strong start to the year, challenges in the industry for 2025, and a focus on margin recovery and growth opportunities. The company remains confident in its outlook, emphasizing pricing discipline and maintaining a strong value proposition in the market.

Humana surpasses Q2 expectations, addresses cost pressures for growth

Humana's Q2 2024 performance exceeded expectations, driven by strong Medicare business and growth in Medicaid and primary care segments.
Challenges such as medical cost pressures were addressed through mitigation measures, while opportunities lie in strategic initiatives and long-term planning.
The company's focus on value, disciplined cost management, and operational efficiency position it well for sustained growth and value creation.

Humana surpasses Q3 expectations, eyes growth through efficiency and investments

Humana's Q3 performance exceeded expectations, with a focus on balancing earnings and investments. The company is strategically positioned to drive growth through membership expansion and operational efficiency. Challenges include managing costs and understanding market dynamics, with opportunities in improving Stars ratings and expanding senior care services.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

SAN DIEGO--(BUSINESS WIRE)---- $HUM #HUM--Robbins LLP is Investigating Allegations that Humana, Inc. (HUM) Misled Investors Regarding its Business Prospects.

Humana, Inc. Investor Notice: Robbins LLP Reminds Stockholders to Seek Representation in the HUM Class Action

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Humana Inc. (“Humana” or the “Company”) (NYSE: HUM) common stock between July 27, 2022, and January 24, 2024, inclusive (the “Class Period”). Humana investors have until August 2, 2024 to file a lead plaintiff motion. If you suffered a loss on your Humana investments.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Humana Inc. (HUM) Investors

LOS ANGELES, CA / ACCESSWIRE / June 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humana Inc. ("Humana" or "the Company") (NYSE:HUM) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 27, 2022 and January 24, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before August 2, 2024.

Investors with Losses from Humana Inc.: Schall Law Firm Encourages You to Reach Out Before the Deadline

NEW YORK , June 6, 2024 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Humana Inc. (NYSE: HUM) between July 27, 2022 and January 24, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.

ROSEN, A LEADING LAW FIRM, Encourages Humana Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUM

SAN DIEGO, June 06, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed on behalf of purchasers or acquirers of Humana Inc. (NYSE: HUM) (“Humana” or the “Company”) common stock between July 27, 2022 and January 24, 2024, inclusive (the “Class Period”), charging the Company and certain current senior executive officers with violations of the federal securities laws.   Humana investors have until August 2, 2024 to seek appointment as lead plaintiff of the class action lawsuit.

INVESTOR ALERT:   DiCello Levitt LLP Announces the Filings of a Class Action Against Humana Inc. (NYSE: HUM)

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Humana Inc. (“Humana” or the “Company”) (NYSE: HUM) common stock between July 27, 2022, and January 24, 2024, inclusive (the “Class Period”). Humana investors have until August 2, 2024 to file a lead plaintiff motion. Investors suffering losses on their Humana investments are encouraged to contact the Law Offices of Howard G. Smith to discuss t.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Humana Inc. (HUM) Investors

LOS ANGELES, CA / ACCESSWIRE / June 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humana Inc. ("Humana" or "the Company") (NYSE:HUM) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 27, 2022 and January 24, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before August 2, 2024.

Humana Inc. Investors with Losses: Schall Law Firm Urges You to Connect Prior to the Deadline

LOS ANGELES--(BUSINESS WIRE)--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Humana Inc. with Losses to Contact the Firm.

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Humana Inc. with Losses to Contact the Firm

Humana Inc. is having short-term cost challenges and facing constrained rate increases. However, Humana's Medicare Advantage expected to benefit from demographic tailwinds and CenterWell integrated care for growth and cost mitigation. I rate Humana a buy at a price target of $396.

Humana Is Set Up For Long-Term Success

SAN DIEGO, June 04, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of persons and entities that purchased or otherwise acquired Humana, Inc. (NYSE: HUM) common stock between July 27, 2022 and January 24, 2024. Humana is a health insurance company that provides medical benefit plans to approximately 17 million members.

Stockholder Alert: Robbins LLP Informs Investors that a Shareholder Has Filed a Class Action Against Humana, Inc. (HUM)

NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Humana Inc. (“Humana” or the “Company”) (NYSE: HUM) in the United States District Court for the District of Delaware on behalf of all persons and entities who purchased or otherwise acquired Humana common stock between July 27, 2022, and January 24, 2024, both dates inclusive (the “Class Period”). Investors have until August 2, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

HUMANA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Humana Inc. and Encourages Investors to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / June 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humana Inc. ("Humana" or "the Company") (NYSE:HUM) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 27, 2022 and January 24, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before August 2, 2024.

The Schall Law Firm is urging investors who have suffered losses in Humana Inc. to get in touch

Humana (HUM) expands its Medicare Advantage network in Alabama through a new partnership with UAB Health System, offering greater access to enhanced healthcare services.

Humana (HUM) Partners With UAB to Boost Care for MA Members

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Humana Inc. (NYSE: HUM) between July 27, 2022 and January 24, 2024, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 2, 2024. SO WHAT: If you purchased Humana securities during the Class Period you ma.

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Humana Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – HUM

LOS ANGELES , June 4, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humana Inc. ("Humana" or "the Company") (NYSE: HUM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 27, 2022 and January 24, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before August 2, 2024.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Humana Inc. with Losses to Contact the Firm

BOSTON--(BUSINESS WIRE)--athenahealth, a leading provider of network-enabled software and services for medical groups and health systems nationwide along with collaborators Availity, Harmony Park Family Medicine, and Humana (NYSE: HUM), received a 2024 Points of Light Award from KLAS. The group's case study, “Using FHIR Standards to Streamline Prior Authorization Management & Improve Patient Care,” recognized the organizations' work together to modernize the prior authorization process and.

athenahealth, Availity, Harmony Park Family Medicine, and Humana Honored with a 2024 KLAS Points of Light Award for Modernizing Prior Authorization Process

SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning Humana business and prospects, resulting in its stock trading at inflated prices.

HUM INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Humana Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

RADNOR, Pa.--(BUSINESS WIRE)--The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against Humana Inc. (NYSE: HUM) (“Humana” or the “Company”) on behalf of investors who purchased or acquired Humana common stock between July 27, 2022, and January 24, 2024, inclusive (the “Class Period”). This action, captioned Iron Workers Local 401 Annuity Fund v. Humana Inc., et al., Case No. 1:24-cv-00655-UNA, was filed in th.

HUM Investor Alert: Kessler Topaz Meltzer & Check, LLP Files a Securities Fraud Class Action Lawsuit Against Humana Inc. and Encourages Investors With Losses to Contact the Firm

SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the Humana class action lawsuit seeks to represent purchasers or acquirers of Humana Inc. (NYSE: HUM) common stock between July 27, 2022 and January 24, 2024, inclusive (the “Class Period”). Captioned Iron Workers Local 401 Annuity Fund v. Humana Inc., No. 24-cv-00655 (D. Del.), the Humana class action lawsuit charges Humana and certain of Humana's top executives with violations of the Securities Exchange Act of 1934.

HUM INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Humana Inc. Investors with Substantial Losses Have Opportunity to Lead the Humana Class Action Lawsuit

BIRMINGHAM, Ala.--(BUSINESS WIRE)--University of Alabama at Birmingham Health System and Humana sign agreement, expanding Humana's Medicare Advantage provider network in Alabama.

University of Alabama at Birmingham (UAB) Health System and Humana Sign Agreement, Expanding Humana's Medicare Advantage Provider Network in Alabama

Brighthouse Financial

Lemonade

Financial and financial technology stocks have had a decent run ever since interest rates rose. The Financial Select Sector SPDR Fund (NYSEARCA: XLF ) is an exchange-traded fund that tracks 71 equities in the financial sector, including banking and insurance companies.

3 Sorry Insurance Stocks to Sell in May While You Still Can

UnitedHealth Group

Centene

Elevance Health Inc

Shares of U.S. health insurers fell on Wednesday after UnitedHealth Group cited a near-term disturbance around reimbursement rates for Medicaid due to ongoing program-wide enrollment hurdles that began about a year ago.

US health insurer shares fall after UnitedHealth flags Medicaid enrollment issues

Humana (HUM) reported earnings 30 days ago. What's next for the stock?

Why Is Humana (HUM) Up 13.1% Since Last Earnings Report?

LOUISVILLE, Ky. & BOSTON--(BUSINESS WIRE)--Lack of real-time data can present serious barriers to care coordination for patients after they leave the hospital. That challenge was the motivation for an innovative collaboration between Bamboo Health™, the leader in Real-Time Care Intelligence™, Humana and Privia Medical Group (PMG)–Georgia to bridge care gaps for patients enrolled in Medicare Advantage plans. The program was one of only 22 presentations selected for a Points of Light Award on May.

Humana & Privia Medical Group–Georgia Partner with Bamboo Health to Earn KLAS Research Points of Light Award

LOUISVILLE, Ky.--(BUSINESS WIRE)--CenterWell Specialty Pharmacy wins national patient choice award for the sixth time in seven years.

News for Humana Stock (HUM)